Gastrointestinal peptides and bone health

Purpose of reviewTo outline recent developments in research surrounding gastrointestinal peptides and their role in skeletal regulation. Recent findingsBone remodeling is influenced by many regulatory systems, which interact to ensure that the complex demands upon mineralized tissue are met without undue compromise. These include local actions such as mechanical factors, but are dominated by systemic endocrine factors. Although the involvement of hypothalamo-pituitary actions on bone homeostasis is well defined, growing evidence suggests that peripheral tissues and the circulating factors they produce represent an important regulatory axis in bone. Given the critical role of diet in mineral homeostasis, the gastrointestinal tract is a rich source of circulating factors capable of regulating bone homeostasis. After a review of manuscripts on known mechanisms and effects of gastrointestinal peptide on bone, these were summarized. SummaryAlthough clearly an exciting and emergent field of research, more studies are required to define the specific actions of gastrointestinal regulator in bone, in particular, the relative contribution of systemic and local effects, to aid interpretation of their potential impact on human health and disease. Nonetheless, this exciting research will further our understanding on bone physiology and provide novel approaches to therapy in a wide range of skeletal conditions.

[1]  Wei Liu,et al.  Connective tissue growth factor is a downstream mediator for preptin-induced proliferation and differentiation in human osteoblasts , 2010, Amino Acids.

[2]  P. Esbrit,et al.  Exendin-4 exerts osteogenic actions in insulin-resistant and type 2 diabetic states , 2010, Regulatory Peptides.

[3]  J. Holst,et al.  Four-month treatment with GLP-2 significantly increases hip BMD: a randomized, placebo-controlled, dose-ranging study in postmenopausal women with low BMD. , 2009, Bone.

[4]  J. Holst,et al.  Short Bowel Patients Treated for Two Years with Glucagon-Like Peptide 2: Effects on Intestinal Morphology and Absorption, Renal Function, Bone and Body Composition, and Muscle Function , 2009, Gastroenterology research and practice.

[5]  E. Poggiogalle,et al.  Relationships of acylated and des-acyl ghrelin levels to bone mineralization in obese children and adolescents. , 2009, Bone.

[6]  N. Gunes,et al.  Effects of amylin on bone development and egg production in hens. , 2009, Poultry science.

[7]  J. Alonso,et al.  Devazepide, a nonpeptide antagonist of CCK receptors, induces apoptosis and inhibits Ewing tumor growth , 2009, Anti-cancer drugs.

[8]  A. Klibanski,et al.  Peptide YY in adolescent athletes with amenorrhea, eumenorrheic athletes and non-athletic controls. , 2009, Bone.

[9]  P. Esbrit,et al.  Effect of GLP-1 Treatment on Bone Turnover in Normal, Type 2 Diabetic, and Insulin-Resistant States , 2009, Calcified Tissue International.

[10]  W. Zhong,et al.  Ghrelin stimulates proliferation of human osteoblastic TE85 cells via NO/cGMP signaling pathway , 2009, Endocrine.

[11]  J. John Mann,et al.  Lrp5 Controls Bone Formation by Inhibiting Serotonin Synthesis in the Duodenum , 2008, Cell.

[12]  T. Nagao,et al.  Pancreatic polypeptide is secreted from and controls differentiation through its specific receptors in osteoblastic MC3T3-E1 cells , 2008, Peptides.

[13]  A. Klibanski,et al.  Peptide YY (PYY) levels and bone mineral density (BMD) in women with anorexia nervosa. , 2008, Bone.

[14]  M. Goldstein,et al.  Prognostic indicators of changes in bone density measures in adolescent girls with anorexia nervosa-II. , 2008, The Journal of clinical endocrinology and metabolism.

[15]  B. Uzan,et al.  Adrenomedullin is anti‐apoptotic in osteoblasts through CGRP1 receptors and MEK‐ERK pathway , 2008, Journal of cellular physiology.

[16]  R. Wildman,et al.  Change in adipocytokines and ghrelin with menopause. , 2008, Maturitas.

[17]  D. Drucker,et al.  The murine glucagon-like peptide-1 receptor is essential for control of bone resorption. , 2008, Endocrinology.

[18]  J. Holst,et al.  Effects of treatment with glucagon-like peptide-2 on bone resorption in colectomized patients with distal ileostomy or jejunostomy and short-bowel syndrome , 2008, Scandinavian journal of gastroenterology.

[19]  W. Bollag,et al.  Impact of Glucose‐Dependent Insulinotropic Peptide on Age‐Induced Bone Loss , 2007, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[20]  J. Herman,et al.  Peptide YY regulates bone turnover in rodents. , 2007, Gastroenterology.

[21]  K. Yaffe,et al.  Use of antidepressants and rates of hip bone loss in older women: the study of osteoporotic fractures. , 2007, Archives of internal medicine.

[22]  W. Bollag,et al.  Glucose-dependent insulinotropic peptide-overexpressing transgenic mice have increased bone mass. , 2007, Bone.

[23]  J. Alonso,et al.  Cholecystokinin Down-Regulation by RNA Interference Impairs Ewing Tumor Growth , 2007, Clinical Cancer Research.

[24]  J. Holst,et al.  Disassociation of bone resorption and formation by GLP-2: a 14-day study in healthy postmenopausal women. , 2007, Bone.

[25]  W. Bollag,et al.  Effects of glucose-dependent insulinotropic peptide on osteoclast function. , 2007, American journal of physiology. Endocrinology and metabolism.

[26]  J. Richards,et al.  Effect of selective serotonin reuptake inhibitors on the risk of fracture. , 2007, Archives of internal medicine.

[27]  J. Holst,et al.  Bone resorption is decreased postprandially by intestinal factors and glucagon-like peptide-2 is a possible candidate , 2007, Scandinavian journal of gastroenterology.

[28]  Yuichiro Yamada,et al.  Gastric inhibitory polypeptide as an endogenous factor promoting new bone formation after food ingestion. , 2006, Molecular endocrinology.

[29]  H. Morris,et al.  Effects of Amylin Deficiency on Trabecular Bone in Young Mice Are Sex-Dependent , 2006, Calcified Tissue International.

[30]  A. Klibanski,et al.  Elevated peptide YY levels in adolescent girls with anorexia nervosa. , 2006, The Journal of clinical endocrinology and metabolism.

[31]  W. Bollag,et al.  Glucose-dependent insulinotropic polypeptide receptor knockout mice have altered bone turnover. , 2005, Bone.

[32]  K. Park,et al.  Ghrelin stimulates proliferation and differentiation and inhibits apoptosis in osteoblastic MC3T3-E1 cells. , 2005, Bone.

[33]  Bart O. Williams,et al.  Essential Role of β-Catenin in Postnatal Bone Acquisition* , 2005, Journal of Biological Chemistry.

[34]  Hans Clevers,et al.  Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. , 2005, Developmental cell.

[35]  S. Bloom,et al.  Ghrelin, peptide YY, glucose-dependent insulinotropic polypeptide, and hunger responses to a mixed meal in anorexic, obese, and control female adolescents. , 2005, The Journal of clinical endocrinology and metabolism.

[36]  A. Robling,et al.  Inhibition of the serotonin (5-hydroxytryptamine) transporter reduces bone accrual during growth. , 2005, Endocrinology.

[37]  S. Takeda,et al.  Ghrelin Directly Regulates Bone Formation , 2004, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[38]  I. Reid,et al.  Shared pathways of osteoblast mitogenesis induced by amylin, adrenomedullin, and IGF-1. , 2004, Biochemical and biophysical research communications.

[39]  Hui Zheng,et al.  Ghrelin stimulation of growth hormone release and appetite is mediated through the growth hormone secretagogue receptor. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[40]  R. Průša,et al.  Amylin fasting plasma levels are decreased in patients with osteoporosis , 2004, Osteoporosis International.

[41]  C. Laplace,et al.  Amylin inhibits bone resorption while the calcitonin receptor controls bone formation in vivo , 2004, The Journal of cell biology.

[42]  A. Schwartz,et al.  Diabetes Mellitus: Does it Affect Bone? , 2003, Calcified Tissue International.

[43]  J. Holst,et al.  Role of Gastrointestinal Hormones in Postprandial Reduction of Bone Resorption , 2003, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[44]  Yuxiang Sun,et al.  Deletion of Ghrelin Impairs neither Growth nor Appetite , 2003, Molecular and Cellular Biology.

[45]  Mohammad A Ghatei,et al.  Inhibition of food intake in obese subjects by peptide YY3-36. , 2003, The New England journal of medicine.

[46]  C. Schwarzer,et al.  Synergistic Effects of Y2 and Y4 Receptors on Adiposity and Bone Mass Revealed in Double Knockout Mice , 2003, Molecular and Cellular Biology.

[47]  H. Grill,et al.  Meal-related ghrelin suppression requires postgastric feedback. , 2003, Endocrinology.

[48]  K. Kitamura,et al.  Adrenomedullin stimulates the growth of cultured normal human osteoblasts as an autocrine/paracine regulator , 2002, Peptides.

[49]  I. Reid Relationships among body mass, its components, and bone. , 2002, Bone.

[50]  S. Khosla,et al.  Use of site-specific antibodies to characterize the circulating form of big insulin-like growth factor II in patients with hepatitis C-associated osteosclerosis. , 2002, The Journal of clinical endocrinology and metabolism.

[51]  I. Reid Relationships among body mass, its components, and bone 1 1 Published simultaneously at BoneKEy-Oste , 2002 .

[52]  Richard P Lifton,et al.  High bone density due to a mutation in LDL-receptor-related protein 5. , 2002, The New England journal of medicine.

[53]  C. Hartmann,et al.  Cbfa1-independent decrease in osteoblast proliferation, osteopenia, and persistent embryonic eye vascularization in mice deficient in Lrp5, a Wnt coreceptor , 2002, The Journal of cell biology.

[54]  G. Thomas,et al.  Hypothalamic Y2 receptors regulate bone formation. , 2002, The Journal of clinical investigation.

[55]  C. Buchanan,et al.  Preptin derived from proinsulin-like growth factor II (proIGF-II) is secreted from pancreatic islet beta-cells and enhances insulin secretion. , 2001, The Biochemical journal.

[56]  Miikka Vikkula,et al.  LDL Receptor-Related Protein 5 (LRP5) Affects Bone Accrual and Eye Development , 2001, Cell.

[57]  K. Hosoda,et al.  Stomach is a major source of circulating ghrelin, and feeding state determines plasma ghrelin-like immunoreactivity levels in humans. , 2001, The Journal of clinical endocrinology and metabolism.

[58]  B. Wisse,et al.  A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans. , 2001, Diabetes.

[59]  I. Reid,et al.  Effects of calcitonin, amylin, and calcitonin gene-related peptide on osteoclast development. , 2001, Bone.

[60]  R. Bollag,et al.  Glucose-dependent insulinotropic peptide is an integrative hormone with osteotropic effects , 2001, Molecular and Cellular Endocrinology.

[61]  I. Reid,et al.  A potential role for adrenomedullin as a local regulator of bone growth. , 2001, Endocrinology.

[62]  A. Young,et al.  Amylin and Bone Metabolism in Streptozotocin‐Induced Diabetic Rats , 2001, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[63]  O. Smithies,et al.  Extreme hydrops fetalis and cardiovascular abnormalities in mice lacking a functional Adrenomedullin gene. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[64]  V. Coxam,et al.  Amylin inhibits ovariectomy-induced bone loss in rats. , 2000, The Journal of endocrinology.

[65]  H. Rasmussen,et al.  Osteoblast-derived cells express functional glucose-dependent insulinotropic peptide receptors. , 2000, Endocrinology.

[66]  M. Nakazato,et al.  Ghrelin is a growth-hormone-releasing acylated peptide from stomach , 1999, Nature.

[67]  P. Nawroth,et al.  The Effect of Pramlintide (Amylin Analogue) Treatment on Bone Metabolism and Bone Density in Patients with Type 1 Diabetes Mellitus , 1999, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[68]  S. Kahn,et al.  Human aging is associated with parallel reductions in insulin and amylin release. , 1998, American journal of physiology. Endocrinology and metabolism.

[69]  I. Reid,et al.  Systemic administration of amylin increases bone mass, linear growth, and adiposity in adult male mice. , 1998, American journal of physiology. Endocrinology and metabolism.

[70]  Teresa To,et al.  Use of selective serotonin-reuptake inhibitors or tricyclic antidepressants and risk of hip fractures in elderly people , 1998, The Lancet.

[71]  C. Ohlsson,et al.  Growth hormone and bone. , 1998, Endocrine reviews.

[72]  I. Reid,et al.  Adrenomedullin is a potent stimulator of osteoblastic activity in vitro and in vivo. , 1997, American journal of physiology. Endocrinology and metabolism.

[73]  A. Jullienne,et al.  Expression of glucagon‐like peptide 1 receptor in a murine C cell line Regulation of calcitonin gene by glucagon‐like peptide 1 , 1996, FEBS letters.

[74]  A. Crespel,et al.  Effects of glucagon and glucagon-like peptide-1 (7-36) amide (tGLP-1) on C-cells from rat thyroid and medullary thyroid carcinoma CA-77 cell line , 1996, Regulatory Peptides.

[75]  T. Moody,et al.  Regulation of insulin secretion and blood glucose metabolism by adrenomedullin. , 1996, Endocrinology.

[76]  I. Reid,et al.  Amylin stimulates osteoblast proliferation and increases mineralized bone volume in adult mice. , 1995, Biochemical and biophysical research communications.

[77]  R. Hazelwood The Pancreatic Polypeptide (PP-Fold) Family: Gastrointestinal, Vascular, and Feeding Behavioral Implications , 1993, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[78]  V. Tillmann,et al.  Effect of pubertal development and physical activity on plasma ghrelin concentration in boys , 2009, Journal of endocrinological investigation.

[79]  I. Reid,et al.  Preptin, another peptide product of the pancreatic beta-cell, is osteogenic in vitro and in vivo. , 2007, American journal of physiology. Endocrinology and metabolism.

[80]  H. Pols,et al.  Ghrelin and unacylated ghrelin stimulate human osteoblast growth via mitogen-activated protein kinase (MAPK)/phosphoinositide 3-kinase (PI3K) pathways in the absence of GHS-R1a. , 2006, The Journal of endocrinology.

[81]  D. Cocchi,et al.  Ghrelin regulates proliferation and differentiation of osteoblastic cells. , 2005, The Journal of endocrinology.

[82]  J. Hughes,et al.  Cholecystokinin receptors , 2005, Cellular and Molecular Neurobiology.

[83]  M. Bouxsein,et al.  Essential role of beta-catenin in postnatal bone acquisition. , 2005, The Journal of biological chemistry.

[84]  J. Holst,et al.  Reduction of nocturnal rise in bone resorption by subcutaneous GLP-2. , 2004, Bone.

[85]  C. Schwarzer,et al.  Synergistic Effects of Y 2 and Y 4 Receptors on Adiposity and Bone Mass Revealed in Double Knockout Mice , 2003 .

[86]  M. Nakazato,et al.  Plasma ghrelin levels in lean and obese humans and the effect of glucose on ghrelin secretion. , 2002, The Journal of clinical endocrinology and metabolism.

[87]  Mark L. Johnson,et al.  A mutation in the LDL receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait. , 2002, American journal of human genetics.

[88]  A.,et al.  Effects of Glucagon and Glucagon-Like Peptide-l-(736) Amide on C Cells from Rat Thyroid and Medullary Thyroid Carcinoma CA-77 Cell Line , 2001 .